These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19006011)

  • 1. Amisulpride and galactorrhoea: delayed or withdrawal?
    Mendhekar D; Lohia D
    World J Biol Psychiatry; 2009; 10(4 Pt 3):1041-2. PubMed ID: 19006011
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpride treatment for clozapine-induced sialorrhea.
    Praharaj SK; Sarkar S; Sinha VK
    J Clin Psychopharmacol; 2009 Apr; 29(2):189-90. PubMed ID: 19512987
    [No Abstract]   [Full Text] [Related]  

  • 4. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive blepharospasm beginning after withdrawal of veralipride.
    Alonso-Navarro H; Jiménez-Jiménez FJ
    Mov Disord; 2006 Nov; 21(11):2033-4. PubMed ID: 16960858
    [No Abstract]   [Full Text] [Related]  

  • 8. Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride.
    Kopecek M; Bares M; Horácek J
    Neuro Endocrinol Lett; 2005 Aug; 26(4):320. PubMed ID: 16136015
    [No Abstract]   [Full Text] [Related]  

  • 9. Aripiprazole in a patient vulnerable to side effects.
    Dehning S; Riedel M; Müller N
    Am J Psychiatry; 2005 Mar; 162(3):625. PubMed ID: 15741488
    [No Abstract]   [Full Text] [Related]  

  • 10. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
    Joyce JN
    Synapse; 2001 May; 40(2):137-44. PubMed ID: 11252025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galactorrhea with aripiprazole.
    Mendhekar DN; Andrade C
    Can J Psychiatry; 2005 Mar; 50(4):243. PubMed ID: 15898468
    [No Abstract]   [Full Text] [Related]  

  • 13. Two cases of amisulpride overdose: a cause for prolonged QT syndrome.
    Ward DI
    Emerg Med Australas; 2005 Jun; 17(3):274-6. PubMed ID: 15953230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.
    Di Giovanni G; Di Mascio M; Di Matteo V; Esposito E
    J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of tardive dyskinesia in a patient taking amisulpride.
    Masdrakis VG; Papadimitriou GN; Papageorgiou C; Kouzoupis A; Giailoglou D; Soldatos CR
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):586-7. PubMed ID: 17196725
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
    Zink M; Knopf U; Henn FA; Thome J
    Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient hyperglycemia and decreased glucose tolerance during antipsychotic monotherapy with amisulpride.
    Opgen-Rhein C; Neuhaus AH; Dettling M
    J Clin Psychopharmacol; 2007 Feb; 27(1):92-3. PubMed ID: 17224723
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulpiride-induced tardive dystonia.
    Miller LG; Jankovic J
    Mov Disord; 1990; 5(1):83-4. PubMed ID: 1967484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary incontinence associated with amisulpride.
    Mendhekar D; Lohia D
    World J Biol Psychiatry; 2009; 10(4 Pt 3):1045-6. PubMed ID: 18609424
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement of tardive dyskinesia following amisulpride treatment.
    Peritogiannis V; Tsouli S; Zafiris S; Pappas D; Mavreas V
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):748-50. PubMed ID: 16574293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.